O'Toole K S, Paris P M, Heller M B, Stewart R D
J Emerg Med. 1987 Jul-Aug;5(4):267-73. doi: 10.1016/0736-4679(87)90254-x.
Survival rates in cases of bradyasystolic cardiac arrest are uniformly low, being reported at from 0% to 3%. Recent advances in technology and microcircuitry have produced lightweight, portable external pacing devices that are less painful to the patient. In an on-going clinical trial of early transcutaneous pacing, five cases were seen in which transcutaneous pacing was begun at the onset of the patients' rhythm disturbance. All five patients survived to leave the hospital. Three of the patients were treated in the prehospital setting. Because of the rapidity with which pacing can be implemented, the ease of application and simplicity of operation, transcutaneous pacing has several advantages over the placing of transvenous pacemakers in the field or emergency department setting. In hemodynamically-compromising bradydysrhythmias unresponsive to pharmacologic intervention, the early use of transcutaneous pacing may improve survival in a group of patients who might otherwise die.
缓慢性心搏停止性心脏骤停病例的存活率一直很低，报道为0%至3%。技术和微电路方面的最新进展已生产出重量轻、便于携带的体外起搏装置，对患者造成的痛苦较小。在一项正在进行的早期经皮起搏临床试验中，观察到5例在患者心律紊乱发作时就开始经皮起搏的病例。所有5例患者均存活并出院。其中3例患者是在院前环境中接受治疗的。由于起搏实施迅速、应用简便且操作简单，在现场或急诊科环境中，经皮起搏相对于放置经静脉起搏器具有多个优势。在对药物干预无反应的血流动力学受损的缓慢性心律失常中，早期使用经皮起搏可能会提高一组否则可能死亡的患者的存活率。
